Roche has started its financial reporting for 2026 with a 5% fall in first-quarter revenues, hit by the appreciation of the ...

Last year's $2.5 billion acquisition of Dynavax started to deliver, with a 2.1% rise in vaccine sales to €1.3 billion, driven ...

The use of GLP-1s by non-diabetics has risen by 700% since 2019. An alarming statistic largely driven by a consumer frenzy of ...

AbbVie's programme of facility announcements in the US has continued with a new 185-acre campus in Durham, North Carolina, ...

Most insight leaders can now see the strategic potential of AI. They understand where it could help them with faster ...

Sarclisa (isatuximab) has been approved in the US since 2020, initially for relapsed/refractory multiple myeloma before ...

The oral BTK inhibitor race in RMS is now a two-horse affair, with fenebrutinib vying against Novartis' remibrutinib, already ...

MSD has agreed a deal with Google Cloud that will put the tech giant's AI tools in the hands of its 75,000 employees ...

As proven by the news of Merck and NVidia’s new partnership, for example. But while the idea of using AI for drug discovery ...

The first recipients of funding under the UK government's £500 million Sovereign AI programme have been announced, intended ...

The first volunteers in a large-scale trial of Moderna's mRNA-based vaccine against bird flu – long considered to be a ...

The Trump administration has extended the duration of a pilot programme to provide access to obesity drugs through Medicare, ...